Thymalin
Also known as: Thymogen
Last updated: 1/23/2026 Last reviewed: 1/23/2026
At a Glance
Thymalin is described as a thymus-derived polypeptide complex discussed as immunomodulatory in some literatures. Composition can vary by product and batch, and evidence quality is heterogeneous.
⚠️ Research Status: Thymalin is not an approved medication in many jurisdictions. This page is educational and intentionally does not include protocols/dosing.
Mechanism of Action (TBD)
Mechanistic claims are composition-dependent for mixture products and should be tied to primary sources describing the specific preparation.
Evidence Summary
Low Confidence In Vitro ≤3 YearsOne in vitro report describes thymalin effects on markers consistent with hematopoietic stem cell differentiation toward T-cell markers in the studied system. [PMID: 33237528]
Safety & Unknowns
- Mixture/derivation products may have batch-to-batch variability.
- Human clinical efficacy and safety are not established by in vitro evidence.
Regulatory Status
| Region | Status |
|---|---|
| United States (FDA) | Not approved (verify product-specific context) |
| European Union (EMA) | Not approved (verify product-specific context) |
| WADA | Check current list (status may change) |
Changelog
| Date | Change |
|---|---|
| 2026-01-23 | Added dossier and linked primary literature |